You knowwwwww .... a long list of indications is great. But it also complicates valuation (in a good way). All in all, it is great that apabetalone and epigenetics can potentially address so many things, but ultimately we need to hone in on a few indications that look like "sure things" for approval, with large enough markets/margins that make this a "no-brainer" for those real markets and indications for valuations, plus unknown upside for apabetalone firstly, and the hibernating library ultimately.

This has blockbuster, initially, and "future" written all over it, potentially ... sorry folks, slipping into sales mode ... my natural role :)

But, nothing happens, unlesss it happens, ... so get it done. Let's quit dancing around, and get the real show on the road. 

Drunk (kinda), after a few margaritas and some Macallan, and a NY strip. All good :)

glta